Congratulations to @LauraBukavinaMD @jaymsiva @drjkaouk and @ClevelandClinic team on largest external validation of the IBCG IR NMIBC substratification model 📊 2822 patients | 20 years | 3-year recurrence by subgroup: 🟢 IR-low: 12% 🟡 IR-intermediate: 38% 🔴 IR-high: 77% Progression followed the same stepwise pattern. Fine-Gray competing-risk models confirmed significance (p<0.001) - separation held on 12-month landmark analysis, ruling out early-event bias. Yet more evidence that trials enrolling IR NMIBC should stratify by IBCG subgroup at enrollment to be clinically meaningful. Conflating patients with 12% and 77% recurrence risk in the same trial arm is a fundamental problem. Full text: authors.elsevier.com/sd/arti… @IBCG_BladderCA

Attention-deficit/ #hyperactivity disorder stimulant use is associated with reduced semen volume in reproductive-age men: a multi-center analysis 👉 rdcu.be/fj2pS @SanjayVall @CleClinicUro @SahilP31 @BlitzUro @ScottLundyMDPhD @raevti

Can we predict mTESE success? Maybe! T/FSH ratio (oddly!) offers modest predictive success in our multi-institutional @MOBYUSgroup study just published in @FertStert - great work @jaymsiva and entire @CleClinicUro @UMichUrology @HenryFordHealth teams! fertstert.org/article/S0015-…

Check out our manuscript published in @urogoldjournal that examines how varicoceles, hypogonadism, and the treatment thereof affects the risk of incident prostate cancer. bit.ly/481Z9I3 @jaymsiva @ScottLundyMDPhD @SanjayVall @jimhotalingmd @LeilaMomtaziMar

🔹 @IBCG_BladderCA IR stratification → now in @NCCN guidelines 🔹 Our new @BJUIjournal study supports & simplifies it 🔹 3 factors → low / intermediate / high risk IR NMIBC Easy to use in a busy clinic. No loss in accuracy. A practical tool for real🌎 #BladderCancer @ClevelandClinic @CCLRI @CleClinicUro as always free access >> doi.org/10.1111/bju.70269